Summa Equity acquires Axion BioSystems
Summa Equity Fund II (Summa) has acquired a majority stake in Axion BioSystems, a provider of MEA and impedance technology for single-cell analysis. Axion BioSystems provides an integrated technology platform for cell activity monitoring, based on its unique Bioelectronic Assay technology. The instruments are used by academia and biopharma customers,
